The nation of Zimbabwe has turned down a major American health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for confidential data.
This rejection came to light following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesman has since explained that the United States was requesting health data for scientific study and commercial gain but was not willing to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more negotiations to find a agreement acceptable to all parties so the nation's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a related health funding agreement after concerns were filed about the safety of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral deals to boost openness and responsibility.
As per statements, 16 African countries have to date signed similar health pacts, constituting over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy through American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the end products would be available to our citizens should a new pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining frameworks previously established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This system is intended to ensure that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how future collaboration could be designed in a way that honours the sovereignty and interests of both nations."
Health Experts Response
A leading public health body expressed it understood the government's concerns, but suggested that negotiations must proceed considering much of the country's HIV programmes depended on foreign aid.
"Where technical issues exist, such as those involving information security or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
The halted deal underscores the ongoing challenges between accepting vital international aid and safeguarding a country's data in an ever more data-driven world.